Napoleon B. Rutledge Jr., holding the positions of Senior Vice President, Controller, and Chief Accounting Officer at McKesson Corp (NYSE: MCK), executed a transaction involving the sale of common stock valued at $101,612 on June 5, 2026. This disposal encompassed 133 shares of McKesson common stock, which were sold at a price of $764.00 per share. The transaction was carried out in compliance with a Rule 10b5-1 trading plan, which was originally established on March 2, 2026.
Following the completion of this transaction, Mr. Rutledge maintains direct ownership of 632 shares of McKesson common stock. The insider sale takes place as McKesson trades at approximately $769, a figure that remains close to the executive's sale price of $764. According to analysis provided by InvestingPro, the healthcare giant appears to be undervalued, with a calculated Fair Value of $1,057. The company continues to maintain a financial health score rated as "GREAT" at 3.23 and currently trades at a P/E ratio of 20.
Recent financial reporting for McKesson Corporation's fourth quarter of fiscal year 2026 reveals a mixed performance profile. The company successfully surpassed earnings per share (EPS) expectations, achieving an EPS of $11.69 compared to the projected $11.57. However, McKesson fell short on revenue, reporting $92.3 billion against the anticipated $101.23 billion. This discrepancy resulted in a negative revenue surprise of 8.82%.
Concurrently, McKesson has completed a significant investment from Apollo-managed funds within its Medical-Surgical Solutions business. Apollo Funds invested $1.25 billion in convertible preferred equity, thereby acquiring approximately a 13% interest in the unit. This transaction values the Medical-Surgical Solutions business at around $13 billion in total enterprise valuation. These developments reflect McKesson's ongoing strategic initiatives and financial performance.
The healthcare distribution sector faces ongoing scrutiny regarding valuation metrics and operational efficiency. McKesson's financial health score of 3.23 and P/E ratio of 20 provide a framework for assessing its market position relative to fair value estimates of $1,057. The negative revenue surprise of 8.82% highlights potential challenges in revenue generation despite meeting EPS targets.
Risks associated with McKesson include the mixed financial performance indicated by the revenue shortfall and the valuation gap between the current trading price of $769 and the estimated fair value of $1,057. The significant investment from Apollo-managed funds in the Medical-Surgical Solutions business introduces strategic considerations regarding the unit's valuation of $13 billion and the 13% equity interest acquired. Investors should monitor the company's ability to convert backlog into cash flow and manage multi-tier vendor risks within the healthcare supply chain.